In [90, 91], the authors revealed that Mdm2/Mdm-X interaction is a promising target for therapeutic reactivation of the tumor-suppressor gene p53 in cancer treatments and found small molecule inhibitors to disrupt Mdm2/Mdm-X interaction and activate p53 function. This evidence concerns the gene TP53 and cancer.